Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020)
Celldex Therapeutics (CLDX) posted quarterly Long-Term Deferred Tax of $297.3 million for Q4 2020, up 324.52% year-over-year from $70.0 million in Q1 2020, and up 324.52% quarter-over-quarter from $70.0 million in Q4 2019.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends
Celldex Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $297.3 million for Q4 2020.
- In Q4 2020, Long-Term Deferred Tax rose 324.52% year-over-year to $297.3 million; the TTM figure through Dec 2020 stood at $297.3 million (up 324.52% YoY), while the FY2020 annual figure was $297.3 million, up 324.52% from the prior year.
- Long-Term Deferred Tax for Q4 2020 stood at $297.3 million, up from $70.0 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $297.3 million in Q4 2020, with the low at $70.0 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn |